Delving into the Latest Updates on Cytran, Inc. with Synapse

概览

关联

1

项与 Cytran, Inc. 相关的药物

Oglufanide disodium

奥谷法奈二钠

靶点-

作用机制

血管生成抑制剂 [+1]

在研机构-

原研机构

ALZA Corp.

在研适应症-

非在研适应症

获得性免疫缺陷综合征 [+7]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

2

项与 Cytran, Inc. 相关的临床试验

NCT00002445

/ Completed临床3期

A Phase III Randomized Placebo Controlled and Double Blinded Study of IM862 for Patients With Muco-Cutaneous AIDS Associated Kaposi's Sarcoma

The purpose of this study is to see if it is safe and effective to use IM862 to treat Kaposi's sarcoma (KS) in AIDS patients.

开始日期-

申办/合作机构

Cytran, Inc.

NCT00017303

/ Unknown status临床2期

A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. IM-862 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill tumor cells. Combining chemotherapy and IM-862 may kill more tumor cells.
PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy and IM-862 in treating patients who have resected stage III ovarian cancer or primary peritoneal cancer.

开始日期2001-01-01

申办/合作机构

Cytran, Inc.

100 项与 Cytran, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Cytran, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 Cytran, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Cytran, Inc. 相关的转化医学

登录后查看更多信息